Britain Agrees to License “Three-Parent” Baby Approach

The country will be the first to formally allow the technique to be used in humans

Join Our Community of Science Lovers!

By Kate Kelland

Britain on Thursday became the first country to formally license an in-vitro fertilization (IVF) treatment designed to create babies from three people.

In a long-awaited decision, Britain's Human Fertilisation and Embryology Authority (HFEA) gave the final go-ahead for the treatment known as mitochondrial transfer, which doctors say could help prevent incurable inherited diseases.


On supporting science journalism

If you're enjoying this article, consider supporting our award-winning journalism by subscribing. By purchasing a subscription you are helping to ensure the future of impactful stories about the discoveries and ideas shaping our world today.


Britain's parliament last year voted to change the law to allow the treatments if and when they were ready for licensing. This latest HFEA decision means the first babies created by the technique in Britain could be born in 2017.

The government's chief scientific adviser, Mark Walport, praised the decision as a "careful and considered" assessment which put Britain at the forefront of medical advances.

The technique involves intervening in the fertilization process to remove mitochondria, which act as tiny energy-generating batteries inside cells, and which, if faulty, can cause fatal heart problems, liver failure, brain disorders, blindness and muscular dystrophy.

"Mitochondrial donation offers a real opportunity to cure a class of potentially devastating inherited conditions and will bring hope to hundreds of affected families in the UK," said Dagan Wells, a professor at Oxford University's biomedical research center and one of many experts welcoming the decision.

The treatment is known as "three-parent" IVF because the babies, born from genetically modified embryos, would have DNA from a mother, a father and from a female donor.

Jeremy Farrar, director of the Wellcome Trust global health charity, said it was a "landmark day for people living with mitochondrial disease".

Research teams around the world have tested and trialed the techniques in a series of pre-clinical experiments, but as yet they have not been used to treat patients in Britain.

The world's first and so-far only known mitochondrial transfer baby was born earlier this year after U.S. doctors working at a clinic in Mexico helped a Jordanian couple conceive using the new three-way treatment.

It’s Time to Stand Up for Science

If you enjoyed this article, I’d like to ask for your support. Scientific American has served as an advocate for science and industry for 180 years, and right now may be the most critical moment in that two-century history.

I’ve been a Scientific American subscriber since I was 12 years old, and it helped shape the way I look at the world. SciAm always educates and delights me, and inspires a sense of awe for our vast, beautiful universe. I hope it does that for you, too.

If you subscribe to Scientific American, you help ensure that our coverage is centered on meaningful research and discovery; that we have the resources to report on the decisions that threaten labs across the U.S.; and that we support both budding and working scientists at a time when the value of science itself too often goes unrecognized.

In return, you get essential news, captivating podcasts, brilliant infographics, can't-miss newsletters, must-watch videos, challenging games, and the science world's best writing and reporting. You can even gift someone a subscription.

There has never been a more important time for us to stand up and show why science matters. I hope you’ll support us in that mission.

Thank you,

David M. Ewalt, Editor in Chief, Scientific American

Subscribe